Targeting HIF-1α is a prerequisite for cell sensitivity to dichloroacetate (DCA) and metformin

Area of Science:

• Oncology
• Cancer Metabolism
• Drug Discovery

Background:

• Targeting cancer's deregulated energy metabolism is a promising therapeutic strategy.
• DCA and metformin are known metabolic modulators with potential anti-cancer effects.

Purpose of the Study:

• To investigate the synergistic effects of DCA and metformin on cancer cell death.
• To elucidate the role of glycolytic enzymes and HIF-1α in the response to this combination therapy.

Main Methods:

• Combination treatment of cancer cells with DCA and metformin.
• Analysis of cell death induction.
• Measurement of glycolytic enzyme expression (HK2, LDHA, ENO1).
• Investigation of HIF-1α activation effects.

Main Results:

• Combined DCA and metformin significantly induced cancer cell death compared to monotherapy.
• The drug combination downregulated key glycolytic enzymes (HK2, LDHA, ENO1).
• HIF-1α activation counteracted the cell death induced by DCA/metformin and restored glycolytic enzyme expression.

Conclusions:

• DCA and metformin exhibit synergistic anti-cancer effects by targeting energy metabolism.
• HIF-1α plays a critical role in mediating resistance to this metabolic therapy.
• Targeting HIF-1α is essential for optimizing DCA and metformin-based cancer treatment strategies.